Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020 , has now closed.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
- Conference Call and Webcast Today, November 23 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
- ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif. --(BUSINESS WIRE)--Nov. 13, 2020-- Arrowhead Pharmaceuticals, Inc.
View HTML
Toggle Summary Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
- Serum Z-AAT reductions of 86-93% - All patients demonstrated greater than 80% reduction in liver Z-AAT monomer - 3 of 4 patients had a decrease in liver globule involvement - 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97% - All patients showed ALT reductions
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on November 18 , and November 19, 2020 , it will host two key opinion leader (KOL) webinars to discuss the company’s two investigational RNA interference (RNAi) based
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 23, 2020 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2020 .
View HTML
Toggle Summary Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
−        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD −        Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M −       
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming event: Chardan Virtual 4th Annual Genetic Medicines Conference October 6, 2020, 1:30 p.m. EDT – Vince Anzalone, CFA, Arrowhead’s vice
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new
View HTML